Previous 10 | Next 10 |
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December ...
2024-01-09 04:03:33 ET Summary Glaukos Corporation's sales growth remains a key indicator for investors, with a 10% increase in Q3 leading to a 50% increase in stock value over the past 14 months. Long-term trends show that the stock has remained flat over the past 5 years despite...
2023-12-28 10:11:14 ET More on Sight Sciences Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Sight Sciences climbs after update on Medicare coverage for glaucoma procedure Sight Sciences spikes after insider purchases Seeking Alpha’s Quan...
2023-12-26 12:21:27 ET More on Sight Sciences Sight Sciences, Inc. (SGHT) Q3 2023 Earnings Call Transcript Sight Sciences spikes after insider purchases Sight Sciences slumps amid risk for Medicare coverage for glaucoma procedure Seeking Alpha’s Quant ...
2023-12-22 17:51:02 ET More on Glaukos Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript BTIG makes top medtech stock picks for 2024, sees sector stabilizing Glaukos stock jumps 15% on FDA approval of glaucoma drug Seeking Alpha’s Quant Ratin...
2023-12-21 06:45:03 ET Wells Fargo analyst issues BUY recommendation for GKOS on December 21, 2023 07:00AM ET. The previous analyst recommendation was Buy. GKOS was trading at $79.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
2023-12-17 17:48:14 ET More on Abbott Laboratories, Glaukos, etc. Abbott Laboratories: A 'Must-Have' In A Defensive Dividend Growth Portfolio Zimmer Biomet: Still Many Questions After A Solid Year So Far Abbott Laboratories: One Of The Safest Dividend Growth Stocks O...
2023-12-15 13:45:01 ET William Blair analyst issues OUTPERFORM recommendation for GKOS on December 15, 2023 01:49PM ET. The previous analyst recommendation was Outperform. GKOS was trading at $79.83 at issue of the analyst recommendation. The overall analyst consensus : ...
2023-12-14 10:47:34 ET More on Glaukos Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript Truist starts Glaukos at buy, cites glaucoma market opportunity Sight Sciences slumps amid risk for Medicare coverage for glaucoma procedure Seeking Alphaȁ...
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity iDose TR was designed to usher in a new era of interventional glaucoma by enabling a proactive approach with a safe, effective, and durable therapy for patients in need FDA approval...
News, Short Squeeze, Breakout and More Instantly...
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 fin...
Shares of Glaukos Corporation (NYSE: GKOS) traded at a new 52-week high today and are currently trading at $120.11. So far today, approximately 152.81k shares have been exchanged, as compared to an average 30-day volume of 541.53k shares. Glaukos Corporation, an ophthalmic medical technology ...
2024-07-01 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...